The FDA on Thursday awarded six new Commissioner’s National Priority Vouchers for a variety of conditions including lung cancer, rectal cancer and weight loss.

Global pharmaceutical stocks are in focus as the U.S. introduces a new pilot program to lower drug prices for State Medicaid ...

GlaxoSmithKline Inc. was registered by Chase Tribble, a consultant with Counsel Public Affairs Inc. for a number of lobbying ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

Phentermine-topiramate helps with weight loss by suppressing appetite but may cause side effects like dizziness and mood ...

Market Size was valued at around US $11.9 billion in 2024, the market is projected to surge past US $30.4 billion by 2033, expanding at a robust CAGR of 11.2% (2025?2033). This extraordinary growth ...

The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...

A wave of the highly contagious respiratory syncytial virus is beginning to wash over the United States—sending greater numbers of babies and toddlers to the hospital, recent data show.

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

FDA adds six drugs to its priority voucher program as CMS and the White House unveil measures to speed reviews and lower ...

GSK plc has announced that GSK5764227 (GSK'227), its B7-H3-targeted antibody-drug conjugate (ADC), has received Orphan Drug ...

The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.